Les Meilleures Cliniques et Coûts des traitements de cancer de l'utérus en Chine 2026

The standard first-line treatment for uterine cancer in China is surgical resection. Surgeons typically perform a total hysterectomy with bilateral salpingo-oophorectomy. This procedure removes the uterus, ovaries, and fallopian tubes. Specialized centers also use DaVinci robotic or laparoscopic techniques for minimally invasive staging.

• Surgical intervention: Hysterectomy serves as the core treatment for resectable tumors.
• Chemotherapy regimen: The carboplatin and paclitaxel combination is the national standard.
• Adjuvant radiation: Brachytherapy or external beam radiation target intermediate-to-high risk patients.
• Fertility preservation: Oral progesterone therapy is an option for early-stage endometrioid cancer.

Bookimed Expert Insight: Clinical data shows that Chinese oncology centers like Fuda Cancer Hospital often treat advanced cases where standard surgery is insufficient. These specialized facilities utilize cryosurgery and microwave hyperthermia to enhance results for late-stage patients. This focus on thermal ablation offers an alternative when traditional first-line systemic therapy needs local reinforcement.

Patient Consensus: Patients emphasize the importance of having a gynecologic oncologist perform the initial surgery. They note that pathology results from the first operation often dictate the entire future treatment plan.

Chinese oncologists treat endometrial cancer using domestic protocols developed by the Chinese Society of Clinical Oncology. These frameworks integrate international FIGO staging and NCCN standards. Specialists also follow specific molecular consensus to guide precision adjuvant therapies and immunotherapy for recurrent cases.

• CSCO guidelines: Domestic standards categorizing recommendations by evidence levels and local drug availability.
• Molecular consensus: Standardizes testing for POLE and p53abn subtypes to determine treatment.
• FIGO system: The universal gold standard utilized for surgical and pathological cancer staging.
• International frameworks: NCCN and ESGO models provide benchmarks for complex or recurrent cases.

Bookimed Expert Insight: Leading Chinese experts often hold dual leadership roles in national bodies. Dr. Liu Shi Xin at Xiamen Humanity Hospital serves as Vice Chairman for both the Chinese Medical Association and the Chinese Anti-Cancer Association. This ensures treatment plans align strictly with high-level national research and the latest radiation oncology protocols.

Patient Consensus: Patients mention that treatment plans often change after the final pathology report. They recommend asking doctors how local recommendations compare specifically to international NCCN or FIGO benchmarks.

Immunotherapy is available for uterine cancer in China through immune checkpoint inhibitors like PD-1 inhibitors. National medical guidelines integrate these drugs for advanced or recurrent cases. Eligibility depends on molecular biomarker status. This requires specific pathology tests like MSI-H or dMMR profiles to predict drug response.

• Biomarker profile: MSI-H or dMMR status indicates high sensitivity to single-agent immunotherapy drugs.
• Combination therapy: Patients with pMMR/MSS status may receive immunotherapy combined with targeted anti-angiogenic drugs.
• Staging requirements: Doctors prescribe immunotherapy mainly for Stage 3, Stage 4, or metastatic disease.
• Physical fitness: Patients need adequate organ function and any autoimmune conditions must be inactive.

Bookimed Expert Insight: Chinese oncology centers demonstrate a distinct capability in managing late-stage uterine cancer. Fuda Cancer Hospital in Guangzhou has treated over 30,000 international patients using multimodal approaches. They often combine systemic immunotherapy with local therapies like cryosurgery or microwave hyperthermia. This strategy targets the primary tumor while immunotherapy manages microscopic spread throughout the body.

Patient Consensus: Patients emphasize molecular testing is a vital first step before therapy starts. They often recommend visiting large specialized cancer centers to ensure access to the latest drug combinations.

Minimally invasive uterine cancer treatments in China include cryosurgery, NanoKnife ablation, and robotic-assisted surgery. These options benefit high-risk patients who cannot tolerate traditional open surgery due to age or heart conditions. Specialized centers utilize precision radiotherapy like SBRT and brachytherapy to target tumors while sparing healthy tissue.

• Ablation therapies: Cryosurgery and NanoKnife destroy tumors through extreme cold or electrical pulses.
• Radiation techniques: Stereotactic Body Radiation Therapy (SBRT) delivers high-dose radiation without any incisions.
• Robotic systems: Hysterectomies performed with the DaVinci robot require only small 8mm incisions.
• Vascular therapy: Interventional radiology delivers targeted treatment directly to the tumor via catheters.

Bookimed Expert Insight: Fuda Cancer Hospital in Guangzhou provides over 10 types of minimally invasive therapies. This volume-based expertise is significant. While many clinics focus on standard chemotherapy, specialized Chinese centers often prioritize local ablation like microwave hyperthermia. This allows for effective treatment even in advanced stages where surgery is contraindicated.

Patient Consensus: Patients emphasize that non-surgical options like hormone therapy effectively preserve function but require rigorous monitoring. Many recommend seeking expert opinions on robotic approaches when traditional surgery is deemed too risky.

Young women in China can preserve fertility while treating endometrial cancer if they meet strict criteria. Eligibility requires stage IA, grade 1 tumors confined to the lining. Chinese medical centers utilize high-dose progestin therapy or hormone-releasing intrauterine devices. This approach avoids immediate hysterectomy for compliant patients.

• Core eligibility: Patients must be under 40 and have progesterone-receptor positive tumors.
• Treatment methods: Doctors utilize oral megestrol acetate or hysteroscopic tumor resection with hormones.
• Success rates: Clinical centers report complete remission rates between 58% and 89%.
• Pregnancy outcomes: Post-remission pregnancy success using assisted reproductive technology reaches 48% to 52%.

Bookimed Expert Insight: Patient data from JCI-accredited centers like Fuda Cancer Hospital shows a strong shift toward minimally invasive therapies. Chinese oncology protocols often combine metabolic drugs like metformin with hormones to boost treatment response. This reflects a trend where major urban centers manage over 30,000 international cases annually. Such high volumes lead to more refined, fertility-sparing protocols compared to general surgery centers.

Patient Consensus: Patients emphasize that surveillance is intense and requires frequent biopsies and ultrasounds to monitor progress. Many note that a hysterectomy is often still required once childbearing is successfully completed.

Traditional Chinese medicine (TCM) in China is a supportive therapy for endometrial cancer alongside surgery and chemotherapy. Modalities like acupuncture and herbal formulations help manage treatment side effects. These methods aim to improve quality of life and immune function during conventional oncology care.

• Acupuncture therapy: Reduces chemotherapy-induced nausea and vomiting while alleviating cancer-related fatigue and pain.
• Herbal medicine: Specific formulations may stabilize the body defenses and mitigate bone marrow suppression.
• Mind-body exercises: Tai Chi and Qigong promote emotional wellness and improve sleep during recovery.
• Dietary protocols: Tailored plans support digestive health and counteract inflammation after intensive pelvic radiation.

Bookimed Expert Insight: While clinics like Fuda Cancer Hospital focus on minimally invasive technologies like cryosurgery and NanoKnife, they operate within an integrative environment. Data shows that JCI-accredited facilities in China often use TCM to help patients tolerate these advanced procedures. This synergy aims to maintain the patient's physical strength so they do not have to delay scheduled conventional treatments.

Patient Consensus: Patients note that TCM is most valuable for day-to-day functioning and managing the heavy toll of chemotherapy. Most emphasize that herbal treatments should only supplement surgery rather than replacing it to avoid safety risks.